Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Cardiology

Assessing Stroke Risk and Prevention Strategies

At a Glance

For people with atrial fibrillation, stroke prevention depends on regularly reviewing risk factors with a clinician, weighing bleeding risks, and choosing an appropriate blood thinner or, for selected patients, left atrial appendage closure. Never change treatment without medical advice.

The most significant complication of Atrial Fibrillation is not the irregular rhythm itself, but the risk of a stroke. Because the heart’s upper chambers (atria) do not pump effectively during AFib, blood can pool and form clots [1]. If a clot travels to the brain, it can cause a stroke. Fortunately, we have precise ways to measure this risk and effective treatments to lower it.

Calculating Your Stroke Risk: CHA2DS2-VASc

Doctors use a scoring system called CHA2DS2-VASc (pronounced “chads-vask”) to determine your annual risk of stroke. Each letter represents a risk factor that adds points to your total score [2][3]:

  • C: Congestive Heart Failure (1 point)
  • H: Hypertension (High blood pressure, even if treated) (1 point)
  • A: Age 75 or older (2 points)
  • D: Diabetes Mellitus (1 point)
  • S: Stroke/TIA/Systemic Embolism history (2 points. Note: this refers to a prior stroke, TIA, or arterial clot, not an ordinary venous clot such as a DVT.)
  • V: Vascular Disease (prior heart attack or peripheral artery disease) (1 point)
  • A: Age 65–74 (1 point)
  • S: Sex Category (Female) (1 point)

Recently, some guidelines (like the 2024 ESC guidelines in Europe) have moved toward the CHA2DS2-VA score, which removes the “female sex” point to focus more on clinical health factors [4][5]. In this system, female sex is viewed as a “risk modifier” that increases risk when other factors are already present, rather than a stand-alone risk [6]. Guideline thresholds differ by region (often a score of 1 in men or 2 in women prompts consideration of anticoagulation in the US). Give patients a clear instruction to review the score with their doctor rather than self-start or stop anticoagulation based on a calculated score.

Balancing the Risk: HAS-BLED

While blood thinners prevent strokes, they also increase the risk of bleeding. To manage this safely, doctors use the HAS-BLED score to identify high-risk patients who need closer monitoring [7].

  • H: Hypertension (Uncontrolled)
  • A: Abnormal Renal or Liver Function
  • S: Stroke History
  • B: Bleeding History or Predisposition
  • L: Labile INR (if taking Warfarin)
  • E: Elderly (Age > 65)
  • D: Drugs (like Aspirin/NSAIDs) or Alcohol

A high HAS-BLED score (3 or higher) does not mean you cannot take a blood thinner. Instead, it serves as a “warning light” for your doctor to address reversible risks—such as bringing high blood pressure under control or stopping unnecessary aspirin—to make anticoagulation safer for you [7].

Treatment Options for Stroke Prevention

Direct Oral Anticoagulants (DOACs)

For most eligible patients with nonvalvular AF, DOACs (such as apixaban, rivaroxaban, dabigatran, or edoxaban) are the preferred first-line choice [1]. Compared to older medications, DOACs provide similar or better protection against stroke with significantly lower rates of life-threatening bleeding in the brain [8][9]. However, DOACs can increase gastrointestinal bleeding compared with warfarin. They also don’t require the frequent blood tests or dietary restrictions associated with older drugs.

Warfarin

While DOACs are popular, Warfarin is required or generally preferred for patients with mechanical heart valves or moderate-to-severe mitral stenosis [10]. Because DOACs were not studied (or were shown to be less effective) in these specific groups, Warfarin is necessary to ensure protection [11].

Left Atrial Appendage (LAA) Closure

Most AFib-related clots form in a small pouch of the heart called the Left Atrial Appendage. Percutaneous closure (e.g., Watchman) is considered mainly for selected patients with nonvalvular AF who have an appropriate stroke risk and a strict medical contraindication or compelling reason not to take long-term anticoagulation; fall or occupational risk alone does not automatically qualify someone [12]. This device is implanted to “plug” the pouch, preventing clots from escaping [13]. While effective, the procedure has its own complications, does not eliminate all stroke risk or treat AFib, and requires a patient-specific short-term antithrombotic regimen while the device heals [14][15].

Medication Safety Box

Important rules for taking anticoagulants (blood thinners):

  • Never stop or skip doses without your care team’s explicit instruction. A missed dose leaves you unprotected. Ask your doctor exactly what to do if you miss a dose.
  • Drug Interactions: Always check with a pharmacist before taking over-the-counter pain relievers (like ibuprofen/NSAIDs or aspirin) or supplements, which can increase bleeding risk.
  • Dental Work and Surgery: Always inform dentists and surgeons that you take an anticoagulant. Your care team will provide a specific plan for safely pausing it.
  • Watch for Bleeding: Seek immediate medical care for unusually heavy bleeding, vomiting or coughing blood, black or bloody stools, a sudden severe headache, or any significant head injury or fall while anticoagulated.

A “Dynamic” Assessment

Your stroke risk is not a “once and done” calculation. Risk scores are dynamic and should be recalculated at least once a year [16]. As you age, or if you develop new conditions like high blood pressure or diabetes, your risk changes [17]. Research shows that nearly 50% of patients see their risk score increase within just two years of diagnosis [18]. Regular check-ins ensure that your prevention strategy evolves with your health.

Special Considerations

Standard risk scores may be less accurate for certain populations:

  • Advanced Kidney Disease (CKD): In patients on dialysis, these scores are less reliable at predicting individual risk, and treatment must be highly personalized [19][20].
  • Cancer: Active cancer can change both clotting and bleeding risks in ways that CHA2DS2-VASc doesn’t fully capture, requiring a specialized approach by your care team [21][22].

Common questions in this guide

How is stroke risk calculated in atrial fibrillation?
Clinicians commonly use the CHA2DS2-VASc score, or in some guidelines the CHA2DS2-VA score, to add points for factors such as heart failure, high blood pressure, age, diabetes, prior stroke or TIA, and vascular disease. Some guidelines treat female sex as a risk modifier rather than a stand-alone point. Do not start or stop a blood thinner based only on a self-calculated score.
What does a high HAS-BLED score mean?
HAS-BLED identifies bleeding risks that may require attention and closer follow-up while you take an anticoagulant. A score of 3 or higher is a warning to address reversible factors, such as uncontrolled blood pressure or unnecessary medicines, but it does not automatically mean you cannot take a blood thinner.
Which blood thinner is usually used for atrial fibrillation?
For most eligible people with AFib that is not associated with a mechanical valve or moderate-to-severe mitral stenosis, direct oral anticoagulants are usually preferred. Warfarin remains necessary or generally preferred for a mechanical heart valve or moderate-to-severe mitral stenosis, and kidney function and other health factors also affect the choice.
Could a Watchman device replace long-term blood thinners?
Left atrial appendage closure may be considered for selected people with nonvalvular AFib who have an appropriate stroke risk and a strict contraindication or compelling reason not to take long-term anticoagulation. The procedure does not treat AFib or eliminate all stroke risk, and short-term antithrombotic treatment is usually needed while the device heals.
How often should AFib stroke risk be reassessed?
Stroke and bleeding risks should be reviewed at least once a year and whenever your health changes. Getting older or developing conditions such as high blood pressure or diabetes can change the balance between stroke prevention and bleeding risk.
What bleeding symptoms need urgent care while taking an anticoagulant?
Seek immediate medical care for unusually heavy bleeding, vomiting or coughing blood, black or bloody stools, a sudden severe headache, or any significant head injury or fall while taking a blood thinner. Tell the healthcare professionals treating you that you use an anticoagulant, and do not stop or skip doses unless your care team instructs you to do so.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current CHA2DS2-VASc score, and how much does each factor contribute to my overall stroke risk?
  2. 2.Based on my HAS-BLED score, what are the most important reversible bleeding risks we should address (like blood pressure or specific medications)?
  3. 3.Am I a candidate for a DOAC, and which one is best suited for my kidney function and daily routine?
  4. 4.Given my medical history, what are the pros and cons of long-term medication versus a procedure like LAA closure (e.g., Watchman)?
  5. 5.How often should we recalculate these scores as I get older or if my other health conditions change?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves.

    Andrade JG, Meseguer E, Didier R, et al.

    Expert review of cardiovascular therapy 2018; (16(6)):413-418 doi:10.1080/14779072.2018.1475229.

    PMID: 29790365
  2. 2

    Assessing Stroke and Mortality Risk in Heart Failure: The CHA2DS2-VASc Score's Prognostic Value in Patients With and Without Atrial Fibrillation: A Meta-Analysis.

    Abouzid MR, Kamel I, Saleh A, et al.

    Cardiology in review 2024; doi:10.1097/CRD.0000000000000749.

    PMID: 39145638
  3. 3

    Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.

    Melgaard L, Gorst-Rasmussen A, Lane DA, et al.

    JAMA 2015; (314(10)):1030-8 doi:10.1001/jama.2015.10725.

    PMID: 26318604
  4. 4

    Current risk stratification schemes for preventing ischemic stroke in patients with nonvalvular atrial fibrillation: HELT-E2S2 and CHA2DS2-VA scores.

    Tomita H, Okumura K

    Journal of cardiology 2026; (87(2)):136-143 doi:10.1016/j.jjcc.2025.10.005.

    PMID: 41138935
  5. 5

    Efficacy of R2CHA2DS2-VA score for predicting thromboembolism in Thai patients with non-valvular atrial fibrillation.

    Methavigul K, Sairat P, Krittayaphong R,

    BMC cardiovascular disorders 2021; (21(1)):540 doi:10.1186/s12872-021-02370-2.

    PMID: 34772351
  6. 6

    Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc?

    Nielsen PB, Skjøth F, Overvad TF, et al.

    Circulation 2018; (137(8)):832-840 doi:10.1161/CIRCULATIONAHA.117.029081.

    PMID: 29459469
  7. 7

    Multifactorial Risk Stratification in Patients with Heart Failure, Chronic Kidney Disease, and Atrial Fibrillation: A Comprehensive Analysis.

    Iacob MS, Kundnani NR, Sharma A, et al.

    Life (Basel, Switzerland) 2025; (15(5)) doi:10.3390/life15050786.

    PMID: 40430213
  8. 8

    Stroke prevention strategies in high-risk patients with atrial fibrillation.

    Kotalczyk A, Mazurek M, Kalarus Z, et al.

    Nature reviews. Cardiology 2021; (18(4)):276-290 doi:10.1038/s41569-020-00459-3.

    PMID: 33110242
  9. 9

    The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.

    De Caterina R, Ageno W, Agnelli G, et al.

    Thrombosis and haemostasis 2019; (119(1)):14-38 doi:10.1055/s-0038-1675816.

    PMID: 30597497
  10. 10

    Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.

    Fanaroff AC, Vora AN, Lopes RD

    European heart journal supplements : journal of the European Society of Cardiology 2022; (24(Suppl A)):A19-A31 doi:10.1093/eurheartj/suab151.

    PMID: 35185406
  11. 11

    Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.

    De Caterina R, Renda G, Carnicelli AP, et al.

    Journal of the American College of Cardiology 2017; (69(11)):1372-1382 doi:10.1016/j.jacc.2016.12.031.

    PMID: 28302288
  12. 12

    Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation: who should receive it in current clinical practice?

    d'Entremont MA, Healy JS, Jolly SS

    Current opinion in cardiology 2026; (41(1)):10-15 doi:10.1097/HCO.0000000000001270.

    PMID: 41185460
  13. 13

    Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.

    Osmancik P, Herman D, Neuzil P, et al.

    Journal of the American College of Cardiology 2020; (75(25)):3122-3135 doi:10.1016/j.jacc.2020.04.067.

    PMID: 32586585
  14. 14

    Left Atrial Appendage Occlusion Devices Focused on Complications of Therapy.

    Castillo-Rodriguez C, Salguero D, Cruz D, et al.

    Cardiology in review 2025; doi:10.1097/CRD.0000000000001035.

    PMID: 40910780
  15. 15

    Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.

    Søndergaard L, Wong YH, Reddy VY, et al.

    JACC. Cardiovascular interventions 2019; (12(11)):1055-1063 doi:10.1016/j.jcin.2019.04.004.

    PMID: 31171282
  16. 16

    Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients.

    Serna MJ, Rivera-Caravaca JM, López-Gálvez R, et al.

    Revista espanola de cardiologia (English ed.) 2024; (77(10)):835-842 doi:10.1016/j.rec.2024.02.011.

    PMID: 38460882
  17. 17

    Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation.

    Chao TF, Lip GYH, Liu CJ, et al.

    Journal of the American College of Cardiology 2018; (71(2)):122-132 doi:10.1016/j.jacc.2017.10.085.

    PMID: 29325634
  18. 18

    Timing of stroke risk reassessment in atrial fibrillation patients with a CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study.

    Anjum M, Ariansen I, Myrstad M, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2025; (27(10)) doi:10.1093/europace/euaf145.

    PMID: 40704643
  19. 19

    Utility of Risk Scores for Predicting Stroke and Intracranial Bleeding Across Levels of Kidney Function in Two Large Community-Based Cohorts of Older Adults With Atrial Fibrillation.

    Bansal N, Tabada GH, Kang Y, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2026; (88(3)):341-355 doi:10.1053/j.ajkd.2026.03.038.

    PMID: 42142610
  20. 20

    Prior ischemic strokes are non-inferior for predicting future ischemic strokes than CHA2DS2-VASc score in hemodialysis patients with non-valvular atrial fibrillation.

    Bel-Ange A, Itskovich SZ, Avivi L, et al.

    BMC nephrology 2021; (22(1)):179 doi:10.1186/s12882-021-02384-0.

    PMID: 33992086
  21. 21

    Validation of Embolic and Bleeding Risk Scores in Patients With Atrial Fibrillation and Cancer.

    Raposeiras-Roubin S, Abu-Assi E, Marchán A, et al.

    The American journal of cardiology 2022; (180()):44-51 doi:10.1016/j.amjcard.2022.06.044.

    PMID: 35914971
  22. 22

    Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database.

    Truong B, Hornsby L, Fox B, et al.

    Journal of thrombosis and thrombolysis 2024; (57(4)):638-649 doi:10.1007/s11239-024-02958-3.

    PMID: 38504063

This page is for informational purposes only and does not constitute medical advice. Your cardiology team should guide decisions about anticoagulants, bleeding risks, and left atrial appendage closure.

Get notified when new evidence is published on atrial fibrillation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.